| Literature DB >> 34641477 |
Madison L Dirks1, Jared T Seale1, Joseph M Collins2, Owen M McDougal1.
Abstract
Veratrum spp. grow throughout the world and are especially prevalent in high mountain meadows of North America. All parts of Veratrum plants have been used for the treatment of ailments including injuries, hypertension, and rheumatic pain since as far back as the 1600s. Of the 17-45 Veratrum spp., Veratrum californicum alkaloids have been proven to possess favorable medicinal properties associated with inhibition of hedgehog (Hh) pathway signaling. Aberrant Hh signaling leads to proliferation of over 20 cancers, including basal cell carcinoma, prostate and colon among others. Six of the most well-studied V. californicum alkaloids are cyclopamine (1), veratramine (2), isorubijervine (3), muldamine (4), cycloposine (5), and veratrosine (6). Recent inspection of the ethanolic extract from V. californicum root and rhizome via liquid chromatography-mass spectrometry has detected up to five additional alkaloids that are proposed to be verazine (7), etioline (8), tetrahydrojervine (9), dihydrojervine (10), 22-keto-26-aminocholesterol (11). For each alkaloid identified or proposed in V. californicum, this review surveys literature precedents for extraction methods, isolation, identification, characterization and bioactivity to guide natural product drug discovery associated with this medicinal plant.Entities:
Keywords: Veratrum californicum; alkaloid; cyclopamine; drug discovery; natural products
Mesh:
Substances:
Year: 2021 PMID: 34641477 PMCID: PMC8513088 DOI: 10.3390/molecules26195934
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Flower and geographic region for Veratrum spp. addressed in this review.
| Species | Flower | Region | Alkaloid(s) | Other Bioactive Components | Reference |
|---|---|---|---|---|---|
|
| Northern Asia, parts of Europe | Verabenzoamine, veratroilzigadenine, 15-O-(2-Methylbutyroyl)germine, veralosinine, veranigrine, | Et linoleate, β-Sitosterol, resveratrol, oxyresveratrol | [ | |
|
| Asia |
| Resveratrol | [ | |
|
| Parts of Europe and northeastern Asia | [ | |||
|
|
| Asia | Verussurine, verabenzoamine, | Stilbenes, flavonoids, phenols, glyceride | [ |
|
|
| Europe and Asia | [ | ||
|
|
| Europe and Asia | Alkaloids including isorubijervine and rubijervine | [ | |
|
| North America |
| [ | ||
|
| North America | Isorubijervosine, pseudojervine, | [ | ||
|
| North America | [ |
Figure 1Structures of 11 known and proposed alkaloids in Veratrum californicum.
Qualitative assessment of Veratrum californicum alkaloids.
| Identity * | [M+H]+ ( | Predicted Molecular Formula |
|---|---|---|
| Cyclopamine ( | 412.326 | C27H41NO2 |
| Veratramine ( | 410.312 | C27H39NO2 |
| Isorubijervine ( | 414.343 | C27H43NO2 |
| Muldamine ( | 458.370 | C29H47NO3 |
| Cycloposine ( | 574.381 | C33H51NO7 |
| Veratrosine ( | 572.365 | C33H49NO7 |
| Verazine ( | 398.347 | C27H43NO |
| Etioline ( | 414.342 | C27H43NO2 |
| Tetrahydrojervine ( | 430.337 | C27H43NO3 |
| Dihydrojervine ( | 428.320 | C27H41NO3 |
| 22-keto-26-aminocholesterol ( | 416.357 | C27H45NO2 |
| N/A | 576.396 | C33H53NO7 |
| N/A | 574.381 | C33H51NO7 |
| N/A | 576.397 | C33H53NO7 |
| N/A | 410.311 | C27H39NO2 |
| N/A | 412.326 | C27H41NO2 |
* Color coding of sections in Table 2 correspond to alkaloids that have been characterized (green), those that have been proposed, but not confirmed (yellow), and alkaloids that have been detected, but are yet to be identified (red).
Methods of extraction, separation, and identification of Veratrum alkaloids.
| Alkaloid | Plant(s) | Sample Preparation * | Separation Technique | Identification | References |
|---|---|---|---|---|---|
| Cyclopamine ( |
| Soxhlet extraction with ethanol/ammonium hydroxide | HPLC | LC-MS, 1H and 13C NMR | [ |
| Ethanol soak | [ | ||||
| Veratramine ( |
| Ethanol and chloroform extraction | Flash chromatography with silica gel | 1H and 13C NMR, HPLC-MS, crystallization, melting point, and HPLC-CAD. | [ |
|
| Benzene, ammonia, acetic acid, and NaOH extractions | High-speed counter-current chromatography | HPLC, MS and NMR | [ | |
|
| Diethyl ether and dichloromethane extractions | N/A | HPLC-MS | [ | |
| Ethanol and then chloroform extraction | Column chromatography | Crystallization | [ | ||
|
| Crystallization and filtration using 2 N-calcium acetate and acetic acid (Unk plant part) | N/A | Crystallization, melting point, and NMR | [ | |
|
| Dried and ground, ethanol then chloroform extraction | HPLC | HPLC, CAD and MS | [ | |
| Isorubijervine ( |
| Chloroform extraction (Unknown plant part) | Craig countercurrent distribution | N/A | [ |
|
| Methanol extraction | Silica gel column chromatography and MPLC | NMR and ESI-MS. | [ | |
|
| Ethanol and chloroform extraction (Unk plant part) | Flash chromatography with silica gel | IR, LC-MS, 1H and 13C NMR | [ | |
| Muldamine ( |
| Benzene and 5% NH4OH soak (Unk plant part) | Column chromatography with silica gel/benzene/methanol slurry | HPLC-ELSD, MS | [ |
| Cycloposine ( |
| Dried and ground, ethanol then chloroform extraction | HPLC-ELSD | HPLC-MS spectra confirmation | [ |
| Veratrosine ( |
| Ethanol soak, chloroform extraction, alkaloid residue | Silica gel, recrystallization in acetone | HPLC-MS | [ |
|
| Dried and ground, ethanol then chloroform extraction | HPLC-ELSD | |||
| Verazine ( |
| N/A (From aerial plant) | N/A | N/A | [ |
|
| Dried, ground and refluxed with CHCl3 | Vacuum liquid chromatography and column chromatography | N/A | [ | |
|
| EtOAc and MeOH extraction from leaves | Silica gel columns and preparative TLC | MeOH crystallization and DEPT, HETCOR, HMQC, and HMBC NMR | [ | |
|
| Ethanol extraction followed by two CHCl3 extractions (Unknown plant part) | Alkali-treated silica gel and TLC | Specific TLC fractions were recrystallized | [ | |
|
| Three methanol extractions | Silica gel column chromatography twice and HPLC | Recrystallization, ESI-MS, IR, 1H and 13C NMR | [ | |
| Etioline ( |
| Dried and ground, Soxhlet extraction with ethanol, chloroform/methanol extraction | Silica gel | 13C NMR and atom probe chromatography | [ |
| Ethanol extraction from bulbs and then CHCl3 extraction | TLC with chloroform and methanol | TLC with chloroform and methanol | [ | ||
| Tetrahydrojervine ( | N/A | Synthesized only | |||
| Dihydrojervine ( | N/A | Synthesized only | |||
| 22-Keto-26-amino cholesterol ( | N/A | Cholesterol metabolite, proposed | [ |
Summary of bioactivity in Veratrum californicum alkaloids.
| Alkaloid | Method of Testing | Efficacy | Reference |
|---|---|---|---|
| Cyclopamine ( | Inhibition of growth of estrogen receptor positive cell line MCF7 | Significant effects at both 10 and 20 µM | [ |
| Inhibition of proliferation of HEL and TF1a cells | Strong effect at 40 µM | [ | |
| Induced apoptosis in human erythroleukemia cells | 40 µM | [ | |
| Inhibition of growth of LNCaP C4-2B cells | Significant inhibition at 100 nmol/L and IC50 of 11 µmol/L. | [ | |
| Decreased cell viability | <75% viability at 20 µM with 50 ng/mL TRAIL in TRAIL-resistant AGS cells | [ | |
| Inhibition of hRSV infection in vitro | IC50 of 36 nM | [ | |
| Reduction of lung hRSV titers | Reduction by 1.5 logs at 100 mg/kg | [ | |
| Veratramine ( | Inhibition of progression of human prostate metastatic cancer cell line PC-3 | <40% proliferation at 50 µM dose | [ |
| Inhibition of progression of human prostate metastatic cancer cell line PC-3 | <20% migration at 50 µM dose | [ | |
| Number of DNA-strand breaks in the cerebellum and cerebral cortex of mice | In both cerebellum and cerebral cortex: >0.5 µm tail moment with 0.25 µmol/kg dose, >1.0 µm tail moment with 2.5 µmol/kg | [ | |
| Isorubijervine ( | Inhibition of rNaV1.3 | IC50 of 12.14 ± 0.77 µM | [ |
| Inhibition of rNaV1.4 | IC50 of 9.82 ± 0.84 µM | [ | |
| Inhibition of rNaV1.5 | IC50 of 6.962 ± 0.422 µM | [ | |
| Inhibition of rNaV1.5 | 5 µM dose led to 41% decrease in current | [ | |
| Lethal dose in mice | LD50 of 1.14 mg/kg | [ | |
| Muldamine ( | Blocks action potential in squid and crayfish giant axons | Little or no depolarization at 1 × 10−4 M | [ |
| Verazine ( | Antifungal | Minimum inhibitory concentration of 6.2 µg/mL for | [ |
| Antifungal | Minimum inhibitory concentration of 3.1 µg/mL for | [ | |
| Inhibition of melanogenesis in B16 FI mouse melanoma cells | IC50 < 1 µg/mL | [ | |
| Etioline ( | Inhibition of hepatitis B in PLC/PRF/5 cells | EC50 of 2.67 µg/mL | [ |
| Dihydrojervine ( | Inhibition of progression of human prostate metastatic cancer cell line PC-3 | <40% proliferation at 50 µM dose | [ |